MIST II study
This article was originally published in The Gray Sheet
Executive Summary
NMT Medical receives an investigational device exemption to conduct a double-blind, randomized trial to assess migraine headache prevention by using the STARFlex septal repair implant to close the patent foramen ovale (PFO). The announcement comes roughly one month after rival St. Jude received clearance to begin enrollment for a study using its Premere PFO closure device 1("The Gray Sheet" Aug. 29, 2005, p. 12)...
You may also be interested in...
St. Jude Expects Easy Enrollment In New PFO Study For Migraines
St. Jude Medical expects the trial of its Premere patent foramen ovale (PFO) closure device in migraine patients to enroll patients faster than trials of PFO closure to prevent stroke
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.